Cell therapy for central nervous system disorders: Current obstacles to progress

被引：50

作者：

Yasuhara, Takao ^{[1
]}

Kawauchi, Satoshi ^{[1
]}

Kin, Kyohei ^{[1
]}

Morimoto, Jun ^{[1
]}

Kameda, Masahiro ^{[1
]}

Sasaki, Tatsuya ^{[1
]}

Bonsack, Brooke ^{[2
]}

Kingsbury, Chase ^{[2
]}

Tajiri, Naoki ^{[3
,4
]}

Borlongan, Cesario V. ^{[2
]}

Date, Isao ^{[1
]}

机构：

[1] Okayama Univ, Dept Neurol Surg, Grad Sch Med, Okayama, Japan

[2] Univ S Florida, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, Tampa, FL USA

[3] Nagoya City Univ, Grad Sch Med Sci, Dept Neurophysiol & Brain Sci, Nagoya, Aichi, Japan

[4] Nagoya City Univ, Med Sch, Dept Neurophysiol & Brain Sci, Nagoya, Aichi, Japan

来源：

CNS NEUROSCIENCE & THERAPEUTICS | 2020年 / 26卷 / 06期

关键词：

cell therapy; iPS cells; Parkinson's disease; stroke; traumatic brain injury; TRAUMATIC BRAIN-INJURY; MESENCHYMAL STEM-CELLS; DOPAMINE NEURONS; PARKINSONS-DISEASE; ISCHEMIC-STROKE; GENE-THERAPY; RAT MODEL; TRANSPLANTATION; TRIALS; NEUROINFLAMMATION;

D O I：

10.1111/cns.13247

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Cell therapy for disorders of the central nervous system has progressed to a new level of clinical application. Various clinical studies are underway for Parkinson's disease, stroke, traumatic brain injury, and various other neurological diseases. Recent biotechnological developments in cell therapy have taken advantage of the technology of induced pluripotent stem (iPS) cells. The advent of iPS cells has provided a robust stem cell donor source for neurorestoration via transplantation. Additionally, iPS cells have served as a platform for the discovery of therapeutics drugs, allowing breakthroughs in our understanding of the pathology and treatment of neurological diseases. Despite these recent advances in iPS, adult tissue-derived mesenchymal stem cells remain the widely used donor for cell transplantation. Mesenchymal stem cells are easily isolated and amplified toward the cells' unique trophic factor-secretion property. In this review article, the milestone achievements of cell therapy for central nervous system disorders, with equal consideration on the present translational obstacles for clinic application, are described.

引用

页码：595 / 602

页数：8

共 50 条

[31] Chemokines and central nervous system disorders
Karpus, WJ
JOURNAL OF NEUROVIROLOGY, 2001, 7 (06) : 493 - 500
[32] Mitochondria and Central Nervous System Disorders
Knedlik, Tomas
Giacomello, Marta
BIOMOLECULES, 2022, 12 (10)
[33] The microbiome and disorders of the central nervous system
Felice, Valeria D.
O'Mahony, Siobhain M.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2017, 160 : 1 - 13
[34] Taurine and central nervous system disorders
Menzie, Janet
Pan, Chunliu
Prentice, Howard
Wu, Jang-Yen
AMINO ACIDS, 2014, 46 (01) : 31 - 46
[35] Inflammatory disorders of the central nervous system
Giovannoni, G
Baker, D
CURRENT OPINION IN NEUROLOGY, 2003, 16 (03) : 347 - 350
[36] Chemokines and central nervous system disorders
William J. Karpus
Journal of NeuroVirology, 2001, 7 : 493 - 500
[37] Venous disorders of the central nervous system
Willinsky, RA
NEUROIMAGING CLINICS OF NORTH AMERICA, 2003, 13 (01) : XI - XI
[38] Mercury and central nervous system disorders
Fung, YK
Meade, AG
Rack, E
Blotcky, AJ
JOURNAL OF DENTAL RESEARCH, 1997, 76 : 158 - 158
[39] Progress and Promise of Nur77-based Therapeutics for Central Nervous System Disorders
Liu, Lu
Ma, Di
Zhuo, La
Pang, Xinyuan
You, Jiulin
Feng, Jiachun
CURRENT NEUROPHARMACOLOGY, 2021, 19 (04) : 486 - 497
[40] Antioxidant therapy in acute central nervous system injury: Current state
Gilgun-Sherki, Y
Rosenbaum, Z
Melamed, E
Offen, D
PHARMACOLOGICAL REVIEWS, 2002, 54 (02) : 271 - 284

← 1 2 3 4 5 →